Drugs / Sitamaquine
Sitamaquine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00000740 | ? → Sep 1993 | HIV infectious disease, pneumocystosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00381394 | Aug 2006 → Sep 2007 | visceral leishmaniasis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00000863 | ? → Jul 1998 | HIV infectious disease, pneumocystosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sitamaquine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00381394 ↗ |
| Known as | NSC-2452 | ChEMBL registry synonym — accepted as the source's own label CHEMBL57004 ↗ |
| Known as | Sitamaquina | ChEMBL registry synonym — accepted as the source's own label CHEMBL57004 ↗ |
| Known as | Sitamaquine dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL57004 ↗ |
| Known as | WR-6026 | ChEMBL registry synonym — accepted as the source's own label CHEMBL57004 ↗ |
| Modality | Small molecule | “Sitamaquine is an 8-aminoquinoline which is being developed as an oral treatment for visceral leishmaniasis (VL).” NCT00381394 ↗ |
| Route | Oral | “Patients were randomized to receive oral sitamaquine, 2 mg/kg/day, once a day for 21 days across four cohorts” PMID 21633025 ↗ Jun 2011 |